HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Host cells impose a broad range of obstacles to the replication of retroviruses. Tetherin (also known as CD317, BST-2 or HM1.24) impedes viral release by retaining newly budded HIV-1 virions on the surface of cells. HIV-1 Vpu efficiently counteracts this restriction. Here, we show that HIV-1 Vpu ind...
Guardado en:
Autores principales: | , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/44a0c442744b443baf920336e2d7e616 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:44a0c442744b443baf920336e2d7e616 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:44a0c442744b443baf920336e2d7e6162021-11-25T05:47:40ZHIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.1553-73661553-737410.1371/journal.ppat.1000574https://doaj.org/article/44a0c442744b443baf920336e2d7e6162009-09-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19730691/pdf/?tool=EBIhttps://doaj.org/toc/1553-7366https://doaj.org/toc/1553-7374Host cells impose a broad range of obstacles to the replication of retroviruses. Tetherin (also known as CD317, BST-2 or HM1.24) impedes viral release by retaining newly budded HIV-1 virions on the surface of cells. HIV-1 Vpu efficiently counteracts this restriction. Here, we show that HIV-1 Vpu induces the depletion of tetherin from cells. We demonstrate that this phenomenon correlates with the ability of Vpu to counteract the antiviral activity of both overexpressed and interferon-induced endogenous tetherin. In addition, we show that Vpu co-immunoprecipitates with tetherin and beta-TrCP in a tri-molecular complex. This interaction leads to Vpu-mediated proteasomal degradation of tetherin in a beta-TrCP2-dependent manner. Accordingly, in conditions where Vpu-beta-TrCP2-tetherin interplay was not operative, including cells stably knocked down for beta-TrCP2 expression or cells expressing a dominant negative form of beta-TrCP, the ability of Vpu to antagonize the antiviral activity of tetherin was severely impaired. Nevertheless, tetherin degradation did not account for the totality of Vpu-mediated counteraction against the antiviral factor, as binding of Vpu to tetherin was sufficient for a partial relief of the restriction. Finally, we show that the mechanism used by Vpu to induce tetherin depletion implicates the cellular ER-associated degradation (ERAD) pathway, which mediates the dislocation of ER membrane proteins into the cytosol for subsequent proteasomal degradation. In conclusion, we show that Vpu interacts with tetherin to direct its beta-TrCP2-dependent proteasomal degradation, thereby alleviating the blockade to the release of infectious virions. Identification of tetherin binding to Vpu provides a potential novel target for the development of drugs aimed at inhibiting HIV-1 replication.Bastien MangeatGustavo Gers-HuberMartin LehmannMadeleine ZuffereyJeremy LubanVincent PiguetPublic Library of Science (PLoS)articleImmunologic diseases. AllergyRC581-607Biology (General)QH301-705.5ENPLoS Pathogens, Vol 5, Iss 9, p e1000574 (2009) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5 |
spellingShingle |
Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5 Bastien Mangeat Gustavo Gers-Huber Martin Lehmann Madeleine Zufferey Jeremy Luban Vincent Piguet HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. |
description |
Host cells impose a broad range of obstacles to the replication of retroviruses. Tetherin (also known as CD317, BST-2 or HM1.24) impedes viral release by retaining newly budded HIV-1 virions on the surface of cells. HIV-1 Vpu efficiently counteracts this restriction. Here, we show that HIV-1 Vpu induces the depletion of tetherin from cells. We demonstrate that this phenomenon correlates with the ability of Vpu to counteract the antiviral activity of both overexpressed and interferon-induced endogenous tetherin. In addition, we show that Vpu co-immunoprecipitates with tetherin and beta-TrCP in a tri-molecular complex. This interaction leads to Vpu-mediated proteasomal degradation of tetherin in a beta-TrCP2-dependent manner. Accordingly, in conditions where Vpu-beta-TrCP2-tetherin interplay was not operative, including cells stably knocked down for beta-TrCP2 expression or cells expressing a dominant negative form of beta-TrCP, the ability of Vpu to antagonize the antiviral activity of tetherin was severely impaired. Nevertheless, tetherin degradation did not account for the totality of Vpu-mediated counteraction against the antiviral factor, as binding of Vpu to tetherin was sufficient for a partial relief of the restriction. Finally, we show that the mechanism used by Vpu to induce tetherin depletion implicates the cellular ER-associated degradation (ERAD) pathway, which mediates the dislocation of ER membrane proteins into the cytosol for subsequent proteasomal degradation. In conclusion, we show that Vpu interacts with tetherin to direct its beta-TrCP2-dependent proteasomal degradation, thereby alleviating the blockade to the release of infectious virions. Identification of tetherin binding to Vpu provides a potential novel target for the development of drugs aimed at inhibiting HIV-1 replication. |
format |
article |
author |
Bastien Mangeat Gustavo Gers-Huber Martin Lehmann Madeleine Zufferey Jeremy Luban Vincent Piguet |
author_facet |
Bastien Mangeat Gustavo Gers-Huber Martin Lehmann Madeleine Zufferey Jeremy Luban Vincent Piguet |
author_sort |
Bastien Mangeat |
title |
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. |
title_short |
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. |
title_full |
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. |
title_fullStr |
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. |
title_full_unstemmed |
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. |
title_sort |
hiv-1 vpu neutralizes the antiviral factor tetherin/bst-2 by binding it and directing its beta-trcp2-dependent degradation. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2009 |
url |
https://doaj.org/article/44a0c442744b443baf920336e2d7e616 |
work_keys_str_mv |
AT bastienmangeat hiv1vpuneutralizestheantiviralfactortetherinbst2bybindingitanddirectingitsbetatrcp2dependentdegradation AT gustavogershuber hiv1vpuneutralizestheantiviralfactortetherinbst2bybindingitanddirectingitsbetatrcp2dependentdegradation AT martinlehmann hiv1vpuneutralizestheantiviralfactortetherinbst2bybindingitanddirectingitsbetatrcp2dependentdegradation AT madeleinezufferey hiv1vpuneutralizestheantiviralfactortetherinbst2bybindingitanddirectingitsbetatrcp2dependentdegradation AT jeremyluban hiv1vpuneutralizestheantiviralfactortetherinbst2bybindingitanddirectingitsbetatrcp2dependentdegradation AT vincentpiguet hiv1vpuneutralizestheantiviralfactortetherinbst2bybindingitanddirectingitsbetatrcp2dependentdegradation |
_version_ |
1718414454543089664 |